SaaS oncology software company in Europe for sale

• Revenue: > 3M EUR
• Employees: > 50
• Investment amount: > 5M EUR
• Location of the SaaS oncology software company: Europe
• Reason for sale: The owners want to grow the company in Europe, therefore are looking to talk to interested investors
• #CFIE ITS210

The company for sale is a software solution provider that enables oncology medical centres to find better cure and medication to cancer patients. The solution produces molecular diagnosis and creates personalized therapies that target the specific medical conditions of a patient. Using AI models, the product is able to match genetic mutations to potential therapies. The AI oncology algorithm is integrated into a decision support system that uses the received data and defines a particular drug that is the most effective against the molecular genetic cause of the patient’s cancer. The company for sale registers more than 3m Euro revenue and has significant growth potential to be able to launch its products to new markets. It has the capability to become a global distributor of predictive AI based medical solutions. The team is formed of around 40 highly skilled professionals specialized in algorithm development, computer and medical sciences. The company is looking for an investor to bring the business to the next level. The required investment amount is around 5M Euro and will be used to streamline business operation, validate the AI algorithm, improve database and further automations and to develop detailed roadmap for market authorisation as a diagnostic device (FDA and EMA).

The company for sale is a health information enterprise specialized in developing high-class software as medical device (SaMD) solutions that propose innovative ways for treating cancer. The products determine the individual molecular genetic profile of the patient’s tumour and use it for identifying the best available cancer drug able to treat every cancer patient. The company collaborates with oncology centers and operates with molecular diagnostics and clinical trials to develop information technology systems and methods that help in studying the molecular genetic alteration in cancer. The doctors in the team are able to evaluate various treatment options and to propose new therapies and cure for the cancer patients.

Cancer is currently treated by oncologists based on the drug which is the most effective at the highest percent in a group of patients, based on comparative randomized clinical trials. The issue here is that what works for one particular patient may not work for another and this may eventually cost the life of a patient. Here the need to register new drugs and cancer treatments that could respond better to the specific conditions of a certain patient. However, this process costs many resources and there is public pressure to reduce medical costs.

The company’s SaaS oncology software solution solves this issue by making it possible to identify a specific treatment that targets a particular client. The company developed and now provides a registered medical procedure guided by its proprietary medical software. The current business model includes End-To-End decision support for precision oncology, centred around the prioritized recommended therapy as calculated by a proprietary algorithm developed by the team. The company either uses the results of market leading molecular diagnostic service providers reports or orders molecular diagnostics from its partners to feed the SaMD. A set price is charged for the decision support services and per each diagnostic ordered. The future and desired business model includes making SaMD as a diagnostic device to be licensed globally.

The company provides End-to-End services such as: licencing SaMD to large oncology centers, obtaining molecular diagnostics testing, providing virtual molecular tumour board, treatment priority calculation and clinical interpretation.

• The company developed a SaaS oncology software solution
• The solution uses AI algorithms to identify the suited treatment for a specific cancer patient
• The company has the potential to become global provider
• The owners are looking to talk with potential investors that are interested to take the business to the next level